Vascular endothelial growth factor and immunosuppression in cancer: Current knowledge and potential for new therapy

Expert Opinion on Biological Therapy

Volumn 7, Issue 4, 2007, Pages 449-460

  Johnson, Benjamin F ^a   Clay, Timothy M ^a   Hobeika, Amy C ^a   Lyerly, H Kim ^a   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Antiangiogenic; Cancer; Dendritic cells; Nuclear factor B; Tumor; Vaccine; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; B7 ANTIGEN; BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; ENDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; MONOCLONAL ANTIBODY; PLACENTAL GROWTH FACTOR; PROVENGE; SEMAXANIB; SHI QUAN DA BU TANG; SODIUM PYROGLUTAMATE; THALIDOMIDE DERIVATIVE; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL FUNCTION; CELL LINE; CELL MATURATION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; DENDRITIC CELL; DRUG WITHDRAWAL; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LEWIS CARCINOMA; LUNG CANCER; LUNG METASTASIS; LYMPHOMA; MELANOMA; MONOTHERAPY; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ANTAGONISM; EXPERT WITNESS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DENDRITIC CELLS; EXPERT TESTIMONY; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34047131797     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.4.449     Document Type: Review

References (111)

1. SALMON JS, LOCKHART AC, BERLIN J: Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest. (2005) 23(8):712- 726.
2. JAIN RK, DUDA DG, CLARK JW, LOEFFLER JS: Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. (2006) 3(1):24-40. •• Comprehensive review of clinical success and failure with anti-VEGF treatment strategies, focusing on bevacizumab and determination of optimal use.
3. RANIERI G, PATRUNO R, RUGGIERI E et al.: Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. (2006) 13(16):1845-1857. • Review of bevacizumab use with focus on translation from murine studies using A4.6.1 to clinical application.
4. O'DWYER PJ: The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist (2006) 11(9):992-998.
5. DUNN G, OLIVER KM, LOKE D, STAFFORD ND, GREENMAN J: Dendritic cells and HNSCC: a potential treatment option? (Review). Oncol. Rep. (2005) 13(1):3-10.
6. GROLLEAU A, SLOAN A, MULE JJ: Dendritic cell-based vaccines for cancer therapy. Cancer Treat. Res. (2005) 123:181-205.
7. SORURI A, ZWIRNER J: Dendritic cells: limited potential in immunothetapy. Int. J. Biochem. Cell Biol. (2005) 37(2):241-245.
8. EVEL-KABLER K, CHEN SY: Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol. Ther. (2006) 13(5):850-858.
9. SAITO H, FRLETA D, DUBSKY P, PALUCKA AK: Dendritic cell-based vaccination against cancer. Hematol. Oncol. Vlin. North Am. (2006) 20(3):689-710. •• Review summarizing both DC vaccine treatment strategies as well as potential for new modifications to enhance therapeutic success.
10. BROXMEYER HE, COOPER S, LI ZH et al.: Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int. J. Hematol. (1995) 62(4):203-215.
11. GABRILOVICH DI, CHEN HL, GIRGIS KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2(10):1096-1103. •• Critical paper establishing a line of work by this laboratory on VEGF and DC function in tumors and potential for therapeutic targets.
12. GRIFFIOEN AW, TROMP SC, HILLEN HF: Angiogenesis modulates the tumour immune response. Int. J. Exp. Pathol. (1998) 79(6):363-368.
13. O'BYRNE KJ, DALGLEISH AG, BROWNING MJ, STEWARD WP, HARRIS AL: The relationship berween angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer (2000) 36(2):151-169.
14. SENGER DR, BROWN LF, CLAFFEY KP, DVORAK HF: Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis (1994) 14(1-6):385-394.
15. TJWA M, LUTTUN A, AUTIERO M, CARMELIET P: VEGF and PlGF: two pleiottopic growth factors with distinct roles in development and homeostasis. Cell Tissue Res. (2003) 314(1):5-14.
16. ROY H, BHARDWAJ S, YLA-HERTTUALA S: Biology of vascular endothelial growth factors. FEBS Lett. (2006) 580(12):2879-2887. •• Detailed review of VEGF from molecular and physiologic perspectives.
17. SENGER DR, VAN DE WATER L, BROWN LF et al.: Vasculat permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. (1993) 12(3-4):303-324.
18. SUNDERKOTTER C, STEINBRINK K, GOEBELER M, BHARDWAJ R, SORG C: Macrophages and angiogenesis. J. Leukoc. Biol. (1994) 55(3):410-422.
19. FOLKMAN J: Tumor angiogenesis: therapeutic implicarions. N. Engl. J. Med. (1971) 285(21):1182-1186.
20. FOLKMAN J, MERLER E, ABERNATHY C, WILLIAMS G: Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. (1970 133(2):275-288.
21. SENGER DR, GALLI SJ, DVORAK AM et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219(4587):983-985.
22. FERRARA N, HENZEL WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. (1989) 161 (2):851-858.
23. FOLKMAN J: The role of angiogenesis in tumor growth. Semin. Cancer Biol. (1992) 3(2):65-71.
24. SHIBUYA M, SEETHARAM L, ISHII Y et al.: Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Princess Takamatsu Symposia (1994) 24:162-170.
25. GABRILOVICH D, ISHIDA T, OYAMA T et al.: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood (1998) 92(11):4150-4166.
26. SAITO H, TSUJITANI S, IKEGUCHI M, MAETA M, KAIBARA N: Relationship between the expression of vascular endothelial growth factor and the density of dendridc cells in gastric adenocarcinoma tissue. Br. J. Cancer (1998) 78(12):1573-1577.
27. ISHIDA T, OYAMA T, CARBONE DP, GABRILOVICH DI: Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol. (1998) 161(9):4842-4851.
28. ALMAND B, RESSER JR, LINDMAN B et al.: Clinical significance of defective dendritic cell differentiation in cancel. Clin. Cancer Res. (2000) 6(5):1755-1766. • Older, but effective research establishing the role and behavior of DCs in cancer patients, including a discussion of ImCs.
29. OHM JE, SHURIN MR, ESCHE C et al.: Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J. Immunol. (1999) 163(6):3260-3268.
30. OHM JE, CARBONE DP: VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. (2001) 23(2-3):263-272.
31. OHM JE, CARBONE DP: Immune dysfunction in cancer patients. Oncology (Williston Park, NY) (2002) 16(1 Suppl. 1):11-18.
32. OHM JE, GABRILOVICH DI, SEMPOWSKI GD et al.: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood (2003) 101(12):4878-4886.
33. LISSONI P, MALUGANI F, BONFANTIA et al.: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J. Biol. Regul. Homeost. Agents (2001) 15(2):140- 144.
34. TAKAHASHI A, KONO K, ITAKURA J et al.: Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology (2002) 62(2):121-127.
35. STRAUSS L, VOLLAND D, KUNKEL M, REICHERT TE: Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci. Monit. (2005) 11(8):BR280-BR292.
36. SOKER S, FIDDER H, NEUFELD G, KLAGSBRUN M: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. (1996) 271(10):5761-5767.
37. SOKER S, TAKASHIMA S, MIAO HQ, NEUFELD G, KLAGSBRUN M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 92(6):735-745.
38. KUSMARTSEV S, GABRILOVICH DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. (2002) 51(6):293-298. •• Summary of ImCs in cancer-induced immunosuppression in both murine and human systems.
39. ALMAND B, CLARK JI, NIKITINA E et al.: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. (2001) 166(1):678-689.
40. + T lymphocytes.
41. BRONTE V, WANG M, OVERWIJK WW et al.: Apoptotic death of CD8+ T lymphocytes aftet immunization: induction of a suppressive population of Mac-1+/Gr-1+cells. J. Immunol. (1998) 161(10):5313-5320.
42. BRONTE V, CHAPPELL DB, APOLLONI E et al.: Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. (1999) 162(10):5728-5737.
43. GABRILOVICH DI, VELDERS MP, SOTOMAYOR EM, KAST WM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells. J. Immunol. (2001) 166(9):5398-5406.
44. SOMBROEK CC, STAM AG, MASTERSON AJ et al.: Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. (2002) 168(9):4333-4343.
45. MASHINO K, SADANAGA N, TANAKA F et al.: Effective strategy of dendtitic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol. Cancer Ther. (2002) 1(10):785-794. •• Defines critical role for Th1-dominant immunity in successful DC-mediated cancer response and implicates Th2 dominance in unsuccessful response.
46. FUJIMOTO T, DUDA RB, SZILVASI A et al.: Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J. Immunol. (1997) 158(12):5619-5626.
47. KUSMARTSEV S, NEFEDOVA Y, YODER D, GABRILOVICH DI: Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. (2004) 172(2):989-999.
48. KUSMARTSEV SA, LI Y, CHEN SH: Gr-1 + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. (2000) 165(2):779-785.
49. KUSMARTSEV S, NAGARAJ S, GABRILOVICH DI: Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. (2005) 175(7):4583-4592.
50. OTSUJI M, KIMURA Y, AOE T, OKAMOTO Y, SAITO T: Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA (1996) 93(23):13119-13124.
51. SONG X, KRELIN Y, DVORKIN T et al.: CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. (2005) 175(12):8200-8208.
52. LI Q, PAN PY, GU P, XU D, CHEN SH: Role of immatute myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. (2004) 64(3): 1130-1139.
53. HUANG B, PAN PY, LI Q et al.: Gr-1+CD15+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. (2006) 66(2):1123-1131.
54. GROUX H, FOURNIER N, COTTREZ F: Role of dendritic cells in the generation of regulatory T cells. Semin. Immunol. (2004) 16(2):99-106.
55. SHEVACH EM: From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity (2006) 25(2):195-201. •• Comprehensive review of Tregs, including roles in cancer.
56. JONULEIT H, SCHMITT E, SCHULER G, KNOP J, ENK AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. (2000) 192(9):1213-1222.
57. DHODAPKAR MV, STEINMAN RM, KRASOVSKY J, MUNZ C, BHARDWAJ N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. (2001) 193(2):233-238.
58. KIM R, EMI M, TANABE K: Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin. Exp. Immunol. (2006) 146(2):189-196.
59. BELLAMY WT, RICHTER L, SIRJANI D et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood (2001) 97(5);1427-1434.
60. KRAUTH MT, SIMONITSCH I, AICHBERGER KJ et al.: Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am. J. Clin. Pathol. (2004) 121(4):473-481.
61. WIMAZAL F, KRAUTH MT, VALES A et al.: Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk. Lymphoma (2006) 47(3):451-460.
62. BRUDER D, PROBST-KEPPER M, WESTENDORF AM et a.: Neuropilin-1: a surface marker of regulatory T cells. Eur. J. Immunol. (2004) 34(3):623-630.
63. BOURBIE-VAUDAINE S, BLANCHARD N, HIVROZ C, ROMEO PH: Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J. Immunol. (2006) 177(3): 1460-1469.
64. ZIEGLER BL, VALTIERI M, PORADA GA et al.: KDR receptor: a key marker defining hematopoietic stem cells. Science (1999) 285(5433): 1553-1558.
65. DIKOV MM, OHM JE, RAY N et al.: Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. (2005) 174(1):215-222.
66. LAXMANAN S, ROBERTSON SW, WANG E et al.: Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem. Biophys. Res. Commun. (2005) 334(1):193-198.
67. TAKAHASHI A, KONO K, ICHIHARA F et al.: Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother. (2004) 53(6):543-550.
68. OYAMA T, RAN S, ISHIDA T et al.: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. (1998) 160(3):1224-1232.
69. DIKOV MM, OYAMA T, CHENG P et al.: Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res. (2001) 61(5):2015-2021.
70. DENK A, WIRTH T, BAUMANN B: NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev. (2000) 11(4):303-320.
71. PETTIT AR, QUINN C, MACDONALD KP et al.: Nuclear localization of RelB is associated with effective antigen-presenting cell function. J. Immunol. (1997) 159(8):3681-3691.
72. AMMON C, MONDAL K, ANDREESEN R, KRAUSE SW: Differential expression of the transcription factor NF-kappaB during human mononuclear phagocyte differentiation to macrophages and dendritic cells. Biochem. Biophys. Res. Commun. (2000) 268(0:99-105. • Article defines role of NF-κB in cell maturation, including individual subunits.
73. NEUMANN M, FRIES H, SCHEICHER C et al.: Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood (2000) 95(1):277-285.
74. RESCIGNO M, MARTINO M, SUTHERLAND CL, GOLD MR, RICCIARDI-CASTAGNOLI P: Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. (1998) 188(11):2175-2180.
75. BURKLY L, HESSION C, OGATA L et al.: Expression of relB is required for the development of thymic medulla and dendritic cells. Nature (1995) 373(6514):531-536.
76. WEIH F, CARRASCO D, DURHAM SK et al.: Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell (1995) 80(2):331-340.
77. GABRILOVICH DI, CHENG P, FAN Y et al.: H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. J. Leukoc. Biol. (2002) 72(2):285-296.
78. ROSEN LS: Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control (2002) 9(2 Suppl.):36-44.
79. FAIRBROTHER WJ, CHRISTINGER HW, COCHRAN AG et al.: Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry (1998) 37(51):17754-17764.
80. LIN P, SANKAR S, SHAN S et al.: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. (1998) 9(1):49-58.
81. MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. (2000) 15(1):29-41.
82. MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. (2001) 19(3):851-856.
83. WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. (2000) 60(4):970-975.
84. GABRILOVICH DI, ISHIDA T, NADAF S, OHM JE, CARBONE DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. (1999) 5(10):2963-2970.
85. NAIR S, BOCZKOWSKI D, MOELLER B et al.: Synetgy between tumor immunotherapy and antiangiogenic therapy. Blood (2003) 102(3):964-971.
86. RINI BI, WEINBERG V, FONG L et al.: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer (2006) 107(1):67-74.
87. PEDERSEN AE, BUUS S, CLAESSON MH: Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett. (2006) 235(2):229-238. •• Novel therapeutic strategy that may be integral to establishing new investigational paths for antiangiogenic therapies.
88. CONDEELIS J, POLLARD JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124(2):263-266.
89. LEWIS CE, POLLARD JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. (2006) 66(2):605-612. •• Comprehensive overview of tumor-associated macrophages and their physiologic roles and potential as therapeutic targets.
90. DIRKX AE, EGBRINK MG, WAGSTAFF J, GRIFFIOEN AW: Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. (2006) 80(6):1183-1196.
91. YILMAZ A, REISS C, WENG A et al.: Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. (2006) 79(3):529-538.
92. SUN X, KANWAR JR, LEUNG E et al.: Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther. (2001) 8(10):719-727.
93. SUN X, KRISSANSEN GW, FUNG PW et al.: Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int. J. Cancer (2005) 113(4):670-677.
94. LI M, HUANG X, ZHUZ et al.: Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J. Immunother. (2001) 24(6):472-481.
95. LI M, HUANG X, ZHU Z et al. The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors. In Vivo (2002) 16(6):577-582.
96. WILCZYNSKA U, KUCHARSKA A, SZARY J, SZALA S: Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim. Pol. (2001) 48(4):1077-1084.
97. BARTLETT JB, DREDGE K, DALGLEISH AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Rev. (2004) 4(4):314-322.
98. HWU WJ, KROWN SE, MENELL JH et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. (2003) 21(17):3351-3356.
99. WIEDMANN MW, CACA K: Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets (2005) 5(3):171-193.
100. TEO SK: Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. (2005) 7(1):E14-E19.
101. VERBON A, JUFFERMANS NP, SPEELMAN P et al.: A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma intetferon in healthy humans. Antimicrob. Agents Chemother. (2000) 44(9):2286- 2290.
102. CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163(1):380-386.
103. CORRAL LG, MULLER GW, MOREIRA AL et al.: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol. Med. (1996) 2(4):506-515.
104. DREDGE K, MARRIOTT JB, MACDONALD CD et al.: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer (2002) 87(10):1166-1172.
105. KIMURA Y, KIDO T, TAKAKU T, SUMIYOSHI M, BABA K: Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. Cancer Sci. (2004) 95(9):758-764.
106. KAMIYAMA H, TAKANO S, ISHIKAWA E, TSUBOI K, MATSUMURA A: Anti-angiogenic and immunomodulatory effect of the herbal medicine 'Juzen-taiho-to' on malignant glioma. Biol. Pharm. Bull. (2005) 28(11):2111-2116.
107. WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95(4):1789-1797.
108. BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. (1999) 5(10):1171-1177.
109. NEMUNAITIS J, STERMAN D, JABLONS D et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96(4):326-331.
110. PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
111. MIRZA N, FISHMAN M, FRICKE I et al.: All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. (2006) 66(18):9299-9307.